Illustrative image – not actual.A new drug policy, aimed at reducing
price controls, is likely to be finalised by October 2001.
The National Pharmaceutical Pricing
Authority (NPPA) is expected to receive new drugs data from the National
Institute of Pharmaceutical Education and Research (NIPER) in September 2001.
NPPA would subsequently submit its recommendations by the end of September
2001, after which the draft new drug policy would be finalised.
The new drug policy is likely to
reduce the span of control from the existing level of 74 drugs to 35 drugs.
Bulk drugs with an annual turnover of Rs.5 crore, would come under the
controlled price regime. The turnover limit for the company manufacturing the
drug would be Rs.20 crore per annum.
As per the existing drug policy, the
criterion for a drug to be under price control is minimum annual turnover of
Rs.1 crore for a bulk drug and Rs.4 crore annual turnover for the company.
Presently, monopoly situation is created if a single formulation drug has over
50 per cent market share.
Meanwhile, the NPPA is reportedly
likely to be revamped and reoriented. It will continue to be entrusted with the
task of price fixation/revision and other related matters. It is proposed to
strengthen the NPPA by providing appropriate powers under the Drug Price
Control Order (DPCO), which would make it mandatory for the manufacturer to
furnish all information as required by the NPPA, and also to regulate drug
prices whenever required.
